EORTC Brain Tumour Group Virtual Meeting
November 3, 2020
Virtual Event
The EORTC Brain Tumour Group Virtual Meeting will be held from 14:00 to 17:00 CET.
| 14.00 | Welcome & Activity Report | M. Weller |
| 14.05 | Report from EORTC HQ | M. Vanlancker |
| 14.20 | Update from BTG Committees | |
| 5 | Translational research & pathology | P. French |
| 5 | Quality assurance | E. Razis |
| 5 | Quality of life | L. Dirven |
| 5 | Imaging | M. Smits |
| 5 | Meningioma | M. Preusser |
| 5 | CNS metastasis | E. Le Rhun |
| 15.00 | Update on completed clinical trials and research projects | |
| 15 | 26053-22054: Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial. | M. van den Bent & P. French |
| 5 | 1320: Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group | M. Preusser |
| 15.30 | Ongoing clinical studies | |
| 5 | 1308: An international randomized phase III study of observation vs. immediate adjuvant radiotherapy for WHO grade II newly diagnosed and recurrent meningioma patients after total surgical resection (ROAM). | M. Preusser |
| 5 | 1419: BTFC Longterm survival in glioblastoma. | C. Hertler |
| 5 | 1608: Study of TG02 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma: a phase Ib study, STEAM. | E. Le Rhun |
| 5 | 1635: IDH mutated 1p/19q intact lower grade glioma following resection: wait or treat? The I-WOT study. | M. van den Bent |
| 10 | 1709: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. | P. Roth |
| 16.00 | Planned clinical trials | |
| 10 | 1634: Standard therapy vs. personalized intensity-modulated therapy for newly diagnosed medulloblastoma in adults: an international phase 0, phase Ib and randomized phase II study (PersoMed-I). | P. Hau |
| 10 | 1926: Romiplostim plus lomustine or lomustine alone at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study. | E. Le Rhun |
| 5 | 2031: AMG 510 in KRASG12C positive non small cell lung cancer patients with brain metastases. | M. Preusser |
| 5 | 2013: Treatment and outcome of patients with primary brain tumors diagnosed according to the revised WHO classification and cIMPACT recommendations. | M. Weller |
| 5 | 2046: Isoquercetin for the prevention of venous thromboembolic events in glioblastoma: a randomized placebo-controlled phase III trial. | E. Le Rhun |
| 16.40 | Current issues, new initiatives & any other business | M. Weller |
| 17.00 | End | |
| Next General Meeting: March, 2021 |
Next events
CDDF Annual Conference 2025
February 3 - February 5
Noordwijk ann Zee
EORTC Brain Tumour Group Spring Meeting
February 21
EORTC HQ, Brussels, Belgium
EORTC Melanoma Group Spring Meeting 2025
March 20 - March 21
Frankfurt, Germany
EORTC Lymphoma Group Spring Meeting 2025
March 21
Copenhagen, Denmark
EORTC Quality of Life Group Spring Meeting 2025
March 27 - March 28
Rotterdam, Netherlands
